# US 2013/0274180 A1 · Pharmaceutical Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274180 A1
- Document ID: US20130274180A1
- Status: Published application
- Kind: A1
- Application number: 13/861,791
- Filed: 2013-04-12
- Published: 2013-10-17
- Earliest claimed: 2005-06-08
- Inventors: Yong Cui; Maura Murphy; Kirk Dinehart; Patricia Hurter; Patrick R. Connelly; Riccardo N. Panicucci
- Web page: https://patentgrep.com/patent/US20130274180A1

## CPC

- A61K 38/07: Tetrapeptides
- A61K 9/145: {with organic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/497: containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Forms and formulations of VX-950 and uses thereof.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

A spray-dried dispersion comprising VX-950, HPMCAS and about 1% wt/wt sodium lauiyl sulfate.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 3)

The spray-dried dispersion of claim 3, wherein less than 40% of the VX-950 is in a crystalline form.

### Claim 7 (depends on 3)

The spray-dried dispersion of claim 3, wherein the VX-950 is substantially free of crystalline VX-950.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 3)

The spray-dried dispersion of claim 3, wherein the VX-950 contained in the spray-dried dispersion has improved physical or chemical stability relative to VX-950 not in the presence of polymer.

### Claim 11 (depends on 3)

The spray-dried dispersion of claim 3, wherein the spray-dried dispersion has a higher glass transition temperature than the glass transition temperature of VX-950 not in a spray-dried dispersion.

### Claim 12 (depends on 3)

The spray-dried dispersion of claim 3, wherein the VX-950 contained in the spray-dried dispersion has a relaxation rate that is lower than the relaxation rate of VX-950 not in a spray-dried dispersion.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 3)

The spray-dried dispersion of claim 3, wherein at least 80% by weight of the VX-950 is in an amorphous form.

### Claim 30 (depends on 29)

The spray-dried dispersion of claim 29, wherein substantially all the VX-950 is in an amorphous form.

### Claim 31 (depends on 3)

The spray-dried dispersion according to claim 3, wherein the VX-950 is a mixture of the L-isomer and the D-isomer.

### Claim 32 (depends on 3)

The spray-dried dispersion according to claim 3, wherein VX-950 is substantially pure L-isomer.

### Claim 33

(canceled)

### Claim 34 (depends on 3)

A pharmaceutical composition comprising the spray-dried dispersion of claim 3.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein the VX-950 is substantially free of crystalline VX-950.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 36)

The pharmaceutical composition of claim 36, wherein the VX-950 contained in the spray-dried dispersion has improved physical or chemical stability relative to VX-950 not in the presence of a polymer.

### Claim 39 (depends on 36)

The pharmaceutical composition of claim 36, wherein the spray-dried dispersion has a higher glass transition temperature than the glass transition temperature of VX-950 not in a spray-dried dispersion.

### Claim 40 (depends on 36)

The pharmaceutical composition of claim 36, wherein the VX-950 contained in the spray-dried dispersion has a relaxation rate that is lower than the relaxation rate of VX-950 not in a spray-dried dispersion.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

A pharmaceutical composition comprising a mixture of:
VX-950, wherein said VX-950 comprises about 30-75% wt/wt of the pharmaceutical composition,
HPMCAS, wherein
said HPMCAS comprises about 30-75% wt/wt of the pharmaceutical composition, and
sodium lauryl sulfate, wherein said sodium lauryl sulfate comprises about 0.5-2% wt/wt of the pharmaceutical composition,
wherein the mixtures is combined with acetone and methylene chloride and spray-dried to form a solid.

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62 (depends on 3)

A process for preparing VX-950 comprising combining VX-950 and HPMCAS with a suitable solvent and spray-drying the mixture to provide the spray-dried dispersion of claim 3.

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69 (depends on 62)

The process according to claim 62, wherein the solvent comprises methylene chloride.

### Claim 70 (depends on 62)

The process of claim 62, wherein the solvent comprises acetone.

### Claim 71 (depends on 62)

The process of claim 62, wherein the solvent comprises from about 0% to about 30% acetone and from about 70% to about 100% methylene chloride.

### Claim 72 (depends on 62)

The process of claim 62, wherein the solvent comprises from about 0% to about 40% acetone and from about 60% to about 100% methylene chloride.

### Claim 73 (depends on 62)

A solid dispersion prepared according to the process of claim 62.

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78 (depends on 3)

The solid dispersion of claim 3, wherein the solid dispersion comprises about 49.5% wt/wt VX-950, about 49.5% wt/wt HPMCAS and about 1% wt/wt sodium lauryl sulfate, wherein the solid dispersion is obtained by spray drying.

### Claim 79 (depends on 46)

The pharmaceutical composition of claim 46, wherein the pharmaceutical composition comprises:
about 49.5% wt/wt VX-950;
about 49.5% wt/wt HPMCAS; and
about 1% wt/wt sodium lauryl sulfate.
